论文部分内容阅读
1临床资料患者女性,36岁,因“左乳癌改良根治术后1年余,双下肢无力10余天”入院。患者1年前因乳腺癌在新辅助化疗6个周期(具体用药不详)后行左乳癌改良根治术。术后病理学报告示乳腺中分化浸润性导管癌,腋窝淋巴结见转移癌(10/23),胸肌间纤维脂肪组织中见癌结节4枚,免疫组化检测显示ER(+++),PR(++),CerbB2(-),Ki67约50%。术后再行辅助化疗2个周期(具体用药不详)。化疗后左侧胸壁放疗35次(总剂量不详),放疗后予以托瑞米芬口服内分泌
A clinical data of female patients, 36 years old, because “left breast cancer more than 1 year after radical mastectomy, lower limb weakness more than 10 days ” admission. Patients with breast cancer after neoadjuvant chemotherapy for 6 cycles (specific medication is unknown) after 1 year of modified radical mastectomy of left breast cancer. Postoperative pathology report showed differentiated invasive ductal carcinoma in breast, metastatic carcinoma in axillary lymph node (10/23), nodular nodules in pectoral muscle fibers (4). Immunohistochemistry showed that ER (+++), PR (++), CerbB2 (-), Ki67 about 50%. Postoperative adjuvant chemotherapy 2 cycles (specific medication is unknown). Left chest wall radiotherapy 35 times after chemotherapy (total dose unknown), after radiotherapy toremifene oral endocrine